Palisade Bio, Inc. announced it has entered into a transformative strategic collaboration with Strand Life Sciences, aimed at advancing precision medicine for ulcerative colitis (UC) therapy. The collaboration with Strand Life Sciences provides Palisade Bio access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors. Leveraging data from over ten UC clinical studies, Palisade has curated a pipeline of 1,600 UC patient samples, including criptomics and clinical outcomes.

This curated dataset, analyzed using in-house tools, enables Palisade to identify biomarkers for selecting UC patient responders, utilizing machine learning to develop a precision medicine approach to patient selection. Palisade Bio is committed to advancing precision medicine solutions for UC and other inflammatory indications. The Company is advancing its collaborative efforts with Strand Life Sciences and other partners to continue driving innovation and transforming the landscape of UC treatment.